Mirati Therapeutics

Mirati

This biotechnology company develops targeted oncology therapies and small molecule inhibitors for patients with lung, colorectal and pancreatic cancers.

Nuvalent

This biopharmaceutical company develops targeted small molecule kinase inhibitors for patients with genomically defined cancers such as non-small cell lung cancer.

Kinnate Biopharma

The company develops small molecule kinase inhibitors for patients with difficult-to-treat cancers featuring specific genetic alterations.

Aprea Therapeutics

This company develops targeted cancer therapies for patients with biomarker-defined tumours and DNA damage response pathway defects.

Avistone Pharmaceuticals

The company develops and manufactures precision oncology medicines, specifically small-molecule targeted therapies for patients with lung cancer and other solid tumours.

SpringWorks Therapeutics

This biopharmaceutical company develops and commercialises targeted oncology medicines and therapies for patients with rare diseases and cancer.

Black Diamond Therapeutics

This clinical-stage company develops precision oncology medicines and small molecule therapies for patients with genetically defined cancers.

Deuteroncology

This company develops deuterated MET kinase inhibitors for the treatment of lung cancer and other advanced solid tumours.